WO2012019053A3 - Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 - Google Patents

Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 Download PDF

Info

Publication number
WO2012019053A3
WO2012019053A3 PCT/US2011/046663 US2011046663W WO2012019053A3 WO 2012019053 A3 WO2012019053 A3 WO 2012019053A3 US 2011046663 W US2011046663 W US 2011046663W WO 2012019053 A3 WO2012019053 A3 WO 2012019053A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
methods
hdm2
impairing
auto
Prior art date
Application number
PCT/US2011/046663
Other languages
French (fr)
Other versions
WO2012019053A2 (en
Inventor
Carlo M. Croce
Flavia Pichiorri
Original Assignee
The Ohio State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Ohio State University filed Critical The Ohio State University
Priority to EP11815348.5A priority Critical patent/EP2600871A2/en
Priority to US13/813,773 priority patent/US20130150430A1/en
Publication of WO2012019053A2 publication Critical patent/WO2012019053A2/en
Publication of WO2012019053A3 publication Critical patent/WO2012019053A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods and compositions for detecting, treating, characterizing, and diagnosing multiple myeloma are described.
PCT/US2011/046663 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 WO2012019053A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11815348.5A EP2600871A2 (en) 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215
US13/813,773 US20130150430A1 (en) 2010-08-04 2011-08-04 Methods for Impairing the P53/HDM2 Auto-Regulatory Loop in Multiple Myeloma Development Using mIR-192, mIR-194 and mIR-215

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37069210P 2010-08-04 2010-08-04
US61/370,692 2010-08-04

Publications (2)

Publication Number Publication Date
WO2012019053A2 WO2012019053A2 (en) 2012-02-09
WO2012019053A3 true WO2012019053A3 (en) 2014-03-20

Family

ID=45560082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046663 WO2012019053A2 (en) 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215

Country Status (3)

Country Link
US (1) US20130150430A1 (en)
EP (1) EP2600871A2 (en)
WO (1) WO2012019053A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487257B1 (en) 2006-01-05 2015-07-01 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US7985584B2 (en) 2006-03-20 2011-07-26 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
ES2562077T3 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding RNAnc
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found Materials and methods useful for affecting tumor cell growth, migration and invasion
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
JP2014500258A (en) 2010-11-15 2014-01-09 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Controlled release mucoadhesion system
GB2486424A (en) * 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (en) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション Methods and compositions relating to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
EP3565607A4 (en) 2017-01-09 2020-11-18 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
EP3784252A4 (en) * 2018-04-18 2022-03-16 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
WO2021001841A1 (en) 2019-07-04 2021-01-07 Lumus Ltd. Image waveguide with symmetric beam multiplication
US11561335B2 (en) 2019-12-05 2023-01-24 Lumus Ltd. Light-guide optical element employing complementary coated partial reflectors, and light-guide optical element having reduced light scattering
TW202309570A (en) 2021-08-23 2023-03-01 以色列商魯姆斯有限公司 Methods of fabrication of compound light-guide optical elements having embedded coupling-in reflectors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090209450A1 (en) * 2006-03-20 2009-08-20 The Ohio State University MicroRNA Fingerprints During Human Megakaryocytopoiesis
US20100099200A1 (en) * 2007-03-16 2010-04-22 Covalx Ag Direct mass spectrometric analysis of drug candidates targeting protein complexes
US20100104662A1 (en) * 2007-02-27 2010-04-29 Rosetta Genomics, Ltd Composition and methods for modulating cell proliferation and cell death

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209450A1 (en) * 2006-03-20 2009-08-20 The Ohio State University MicroRNA Fingerprints During Human Megakaryocytopoiesis
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20100104662A1 (en) * 2007-02-27 2010-04-29 Rosetta Genomics, Ltd Composition and methods for modulating cell proliferation and cell death
US20100099200A1 (en) * 2007-03-16 2010-04-22 Covalx Ag Direct mass spectrometric analysis of drug candidates targeting protein complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAUN ET AL.: "p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest.", CANCER RES., vol. 68, 2008, pages 10094 - 10104, XP008138920 *
VASSILEV ET AL.: "In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2.", SCIENCE, vol. 303, 2004, pages 844 - 848, XP002338500 *
ZHAO ET AL.: "p53 Mediates the negative regulation of MDM2 by orphan receptor TR3.", EMBO J., vol. 25, 2006, pages 5703 - 5715, XP055136208 *

Also Published As

Publication number Publication date
US20130150430A1 (en) 2013-06-13
EP2600871A2 (en) 2013-06-12
WO2012019053A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012019053A3 (en) Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
MX2019008065A (en) Compositions comprising anti-cd38 antibodies and lenalidomide.
PH12014501108A1 (en) Anti-il-36r antibodies
EP2780465A4 (en) Methods, devices, and kits for obtaining and analyzing cells
GB2522366A (en) Mapping cytosine modifications
SG11201401382QA (en) Hybrid dendrite copolymers, compositions thereof and methods for producing the same
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
WO2014145958A3 (en) Network-based microbial compositions and methods
EP2637702A4 (en) Methods, compositions, cells, and kits for treating ischemic injury
EP2545084A4 (en) Supported metallocene catalyst, method for preparing the same and method for preparing polyolefin using the same
EP2316071A4 (en) Cloud computing gateway, cloud computing hypervisor, and methods for implementing same
PH12014502406B1 (en) Anti-il-23p19 antibodies
SG10201810110RA (en) Extreme pcr
SG11201401383WA (en) Graft dendrite copolymers, and methods for producing the same
WO2015013465A3 (en) Methods and compositions for detecting bacterial contamination
WO2012054747A3 (en) Methods and compositions for treating tumors using myeloid derived suppressor cells
ZA201203603B (en) Lyophilization methods, compositions, and kits
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
EP3272855A4 (en) Liver cells and liver non-parenchymal cells, and methods for preparation thereof
EP2528429A4 (en) Rotary milking station, kit for assembling the same, and methods of assembling and operating associated thereto
WO2012121746A3 (en) Imaging beta cell mass
BR112013012450A2 (en) compositions, detection methods and kits
WO2012106680A8 (en) Methods and compositions for chemical drying and producing struvite
ZA201307104B (en) Compositions, methods, and kits for detecting and indentifying mycobactetia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815348

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13813773

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011815348

Country of ref document: EP